View Document Preview and Link Open Document File Size: 3,02 MB Share Result on Facebook
Company Novartis / Amgen / GM / Sandoz Inc. / / Country United States / / Event FDA Phase / / IndustryTerm biological products / proposed commercial product / drug product / comparator product / reference product / biosimilar product / biological product / manufacturing / biosimilar biological product / clinical product / biosimilar biological products / proposed biosimilar product / / MedicalCondition congenital neutropenia / breast cancer receiving TAC chemotherapy / neutropenia / chronic administration / fever / febrile neutropenia / neutropenia indications / infections / Acute Myelogenous Leukemia / severe neutropenia / idiopathic neutropenia / cyclic neutropenia / / MedicalTreatment leukapheresis / Chemotherapy / / Movie A.D. / / Organization Food and Drug Administration / UV CD / Review Division / European Union / Neupogen FDA Briefing Document Oncologic Drugs Advisory Committee / Advisory Committee / / Person Obama / / Position President / EXECUTIVE / CMC Executive / / Product Neupogen / EP2006 / / Technology Chemotherapy / transplantation / pharmacodynamics / stem cells / / SocialTag 
ODAC Brief BLA[removed]EP2006, a proposed biosimilar to Neupogen FDA Briefing Document